Issue link: https://beckershealthcare.uberflip.com/i/1198635
23 DEVICES & IMPLANTS Misonix acquires Solys Medical — 4 things to know By Alan Condon Misonix completed the acquisition of Solys Medical in September. Four things to know: 1. The acquisition was an all-stock transaction of roughly $109 million in val- ue on the date prior to closing. 2. In the deal, Misonix acquired TheraSkin, Solys Medical's cellular and tis- sue-based wound treatment. 3. The acquisition included the issuance of around 5.7 million new shares to former Solys unitholders. 4. Misonix assumed Solsys' outstanding secured debt of roughly $24 million. n NFL hall of famer becomes brand ambassador for NuVasive By Alan Condon NuVasive appointed NFL hall of famer Jerome Bettis as a brand ambassador. Three things to know: 1. The former Pittsburgh Steelers running back will share his experience with NuVasive's extreme lateral interbody fusion to raise awareness about mini- mally invasive surgery. 2. Mr. Bettis suffered from debilitating back pain before undergoing spine surgery with NuVasive's XLIF. 3. Last week NuVasive launched its Modulus TLIF-A implant, completing its advanced materials science portfolio for posterior interbody fusion tech- niques in transforaminal lumbar interbody fusion procedures. n Zimmer Biomet adds to leadership ranks By Eric Oliver Zimmer Biomet brought Carrie Nichol on board to serve as the company's vice president, controller and chief accounting officer. Ms. Nichol comes to Zimmer Biomet after a tenure at Endo International, where she served in similar positions. She also worked at Haas Group, Ikon Office Solutions and Advanced Metallurgical Group. She began her career as a public accountant at KPMG. She holds an MBA from Villanova (Pa.) University. Zimmer Biomet CFO Suky Upadhyay said, "I look forward to working with Car- rie as we continue our laser focus on transitioning to offense and executing on our strategies to deliver value to our stakeholders around the world." n Medtronic aims to expand Infuse use to TLIF with FDA-backed clinical trial By Laura Dyrda M edtronic received FDA approval to move forward with a prospective, randomized pivotal clinical trial that will examine the use of Infuse in trans- foraminal lumbar interbody fusions. Medtronic began recruiting patients for the trial in September, which could include up to 50 sites and 1,000 patients. The company is also enrolling patients in a separate clin- ical trial, approved in 2017, that examines Infuse for posterolateral fusions. e FDA and Medtronic are working togeth- er to incorporate retrospective safety and ef- ficacy data into the PLF clinical trial. Infuse originally hit the market in 2002 and has been used in 2 million patients since then. "Medtronic continues to invest in scientific evidence on Infuse to continue adding to the growing body of clinical data, and we believe these trials will generate additional data to expand indications, increase access to sur- geons and alleviate pain and restore health for patients around the world," said Jacob Paul, senior vice president and president of Medtronic's spine division in the Restorative erapies Group. Both clinical trials are investigational only. Infuse is a bone morphogenetic protein prod- uct, rhBMP-2. According to Grand View Research, the BMP market was valued at $504.2 million in 2015, but expected to grow through 2024. For the first quarter of the 2020 fiscal year, Infuse sales grew in the low-double digits. n